Jaydutt V Vadgama

Title(s)Professor-in-Residence, Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of East London, London, EnglandB.Sc.1975Biochemistry/Physiology
    University of London, Chelsea College, London, EnglandPh.D. 1981Biochemistry
    University of Michigan, Ann Arbor, MIPost-doctoral FellowshipBiological Chemistry

    Collapse Overview 
    Collapse Overview
    Dr. Vadgama is the Vice President for Research and Health Affairs at Charles R. Drew University of Medicine and Science (CDU). He is a Full Professor of Medicine at CDU and the UCLA David Geffen School of Medicine in the Department(s) of Internal Medicine. Dr. Vadgama has provided significant leadership in growing and sustaining research at CDU over the last two decades. Dr. Vadgama has several additional administrative responsibilities that include Chair of the Institutional Space Committee, Chair of the Ph.D. Planning Committee, establishing the Intellectual Property/Patent Committee at CDU, Institutional Official for IACUC, and chairing several Task Force committees.
    Leadership Experience: Dr. Vadgama continues to serve as Division Chief, Center Director, Vice President, member of the President’s Executive Team, and the Provost’s Team in addition to several additional executive roles. He has over 30 years of direct experience in Academia and Research with a strong understanding of the processes, policies, and procedures necessary to attain academic excellence. He provides significant support and leadership to students, faculty, the Academic Senate, division chiefs, department chairs, deans, provosts, and the University president on matters relevant to research, academic processes, challenges, and growth. Under Dr. Vadgama’s leadership, CDU has set the foundation for establishing a Precision Medicine program's infrastructure to bring genomic-level diagnosis to the translational investigation. He continues to work with faculty, students, and staff to strengthen clinical, basic, and translational research/programs, integrate them with academic programs across campus and develop strong partnerships with UCLA, Cedars, and other institutions. Dr. Vadgama serves on the senior leadership team of the UCLA CTSI Program. At the University president and deans' request, he has represented the University at several national forums on cancer and health disparities. He serves in an advisory capacity to the president and the Executive Team for directing research initiatives at CDU in partnership with other institutions.
    Strength in Diversity: Dr. Vadgama has over 25 years of experience working at Historically Black College and University (HBCU) and Hispanic Serving Institution (HSI). In 1992/3, he was recruited to Charles R. Drew University of Medicine and Science as Director of Laboratory Research and Development to develop Biomedical Sciences research infrastructure that supported underrepresented and underserved undergraduate students, graduate students, medical residents, clinical fellows, postdoctoral fellows, and faculty. Also, during these last 27 years and prior, he has had extensive experience working with underrepresented and under-resourced communities in South Los Angeles and neighboring communities. Dr. Vadgama states: “It continues to be an honor and privilege to be able to make differences in the day to day lives of our students, faculty, staff, and community partners.”
    Translational Cancer Research Experience: Dr. Vadgama has extensive experience in conducting oncology research that integrates clinical, basic, and community-based research. The outcome of these efforts has resulted in the development of translational cancer research at CDU. Research programs in his division focus on 1) genetics and epigenetics; 2) identification of cellular/molecular markers and novel genes for early detection, prevention, and management of breast, colorectal cancer, and prostate cancers; 3) mechanisms associated with bone metastasis from breast cancer; 4) role of mismatch repair proteins and microsatellite instability in colorectal cancer in minority populations; 5) identification and characterization of normal and cancer stem cells in breast and prostate cancers that contribute to drug resistance; 6) cancer outreach and prevention studies. 7) Dr. Vadgama and his research team are making significant

    Impact on understanding how social and epigenomic factors associated with social determinants of health in underserved and under-resourced communities impact health outcomes, focusing on cancer health disparities. Specifically, his team has identified that comorbidities such as Obesity, Diabetes, and Hypertension play a significant role in cancer health disparities.
    He has been a recipient of numerous extramural grants. Recent examples include 1) Identification of novel biomarkers associated with risk for bone metastasis from breast cancer (NIH/NCI CA15083-25S3), and 2) Role of Mismatch Repair Proteins and Microsatellite Instability in Colorectal Cancer in African American and Hispanic patients (CA 15083-25S3). Currently, he is the principal investigator of several center grants at CDU. The CDU/UCLA Cancer Center Partnership has been funded by the National Cancer Institute (U54CA143931) since 2003, with the last renewal for $12.6M (2015-2021). The partnership supports cancer disparities research at CDU and UCLA. It supports programs that develop novel cancer health disparities research. It has developed a state-of-the-art biomarker and biospecimen repository. It provides formal training in cancer research to students, fellows, faculty, community engagement activities, and clinical research studies. In addition, Dr. Vadgama serves as PI for the Accelerating Excellence in Translational Science Center (U54MD007598), recently funded for $18.76M (2019-2025). The overall purpose of the AXIS is to better position CDU for conducting clinical and translational research, especially research focused on health disparities. In response to the COVID-19 pandemic, Dr. Vadgama and the CDU team have obtained several administrative supplements from NIH (>$950K) to study health disparities associated with COVID-19 in African American and Latinx communities in South Los Angeles. They have also obtained funding for Covid-19 Vaccine Trials with Fred Hutch Cancer Center for over $1,9M.
    Other Professional Experience: Dr. Vadgama serves as a reviewer for grants submitted to the NIH, DOD, VHA, and EPSRC. He is Editor-In-Chief of IJBS, Clinics in Oncology Journal, and serves on the editorial board of 14 journals, and an ad-hoc reviewer for 30 peer-reviewed journals. Dr. Vadgama has participated at national and international cancer meetings as chair, co-chair, invited honorary, and keynote speaker. He has also served on several community-partnered panels and conferences and honored with a Distinguished Achievement Award for Research and Community Partnership award from the Watts Area Ministers (WAM). He received the “Unsung Heroes Award” by the National Community Based Organization Network for Dedicated Service and Outstanding Accomplishments in the Field of Community-Based Public Health. In addition to serving on NIH Study Section Review Committees, Dr. Vadgama serves on several advisory boards. To name a few, The Susan G. Komen® African American Health Equity Initiative (AAHEI): AAHEI Community Advisory Board; the University of California Riverside, Center for Health Disparities; and others.

    Teaching and Training Experience: Dr. Vadgama has extensive training students, residents, and fellows in basic, clinical, and translational cancer research. The NIH has funded his training programs since 2004 and serves as a mentor and reviewer for several training programs, including the CTSI and Susan G. Komen Foundation. To date, Dr. Vadgama has mentored 59 postdoctoral and clinical fellows, 34 graduate students, 16 medical students (mostly underrepresented), 149 undergraduate students across the nation, and 35 high school students. Dr. Vadgama serves as a mentor for several funded early-stage investigators at CDU and the UCLA School of Medicine. In addition, he mentors several underrepresented trainees from schools such as CDU, UCLA, UCI, UCR, CSUDH, USC, and others.

    Collapse Research 
    Collapse Research Activities and Funding
    LOC: HIV Vaccine Trials Network
    NIH UM1AI068614Jul 2, 2020 - Nov 30, 2020
    Role: Co-Investigator
    Accelerating Excellence in Translational Science (AXIS)
    NIH/NIMHD U54MD007598Sep 28, 2009 - Feb 29, 2024
    Role: Principal Investigator
    Accelerating Excellence in Translational Science (AXIS)
    NIH U54MD007598Sep 28, 2009 - Feb 29, 2024
    Role: Principal Investigator
    CDU-UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
    NIH/NCI U54CA143931Sep 28, 2009 - Aug 31, 2021
    Role: Principal Investigator
    Drew/UCLA Cancer Partnership Program
    NIH U56CA101599Aug 1, 2009 - Jul 31, 2010
    Role: Principal Investigator
    Charles R. Drew Student Scholar Program
    NIH R25DK067015Sep 30, 2003 - Jul 31, 2009
    Role: Principal Investigator
    NIH R29DK039147Aug 1, 1987 - Nov 30, 1992
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Basal-like breast cancer with low TGFß and high TNFa pathway activity is rich in activated memory CD4 T cells and has a good prognosis. Int J Biol Sci. 2021; 17(3):670-682. Liu D, Vadgama J, Wu Y. PMID: 33767579.
      View in: PubMed   Mentions:    Fields:    
    2. Endometriosis: A Malignant Fingerprint. J Cancer Res Ther Oncol. 2020 Apr; 8(2). DeAngelo C, Tarasiewicz MB, Strother A, Taggart H, Gray C, Shanahan M, Glowacki C, Khandalavala J, Talaska E, Kinnan A, Coté JJ, Edwards AP, Harper-Harrison G, Casey MJ, Hirai TL, Schultz S, Stines L, Vora R, Boudreau D, Burgart J, Shama M, Watson T, Strasheim L, Thompson R, Lawlor R, Joyce K, Magnuson CM, Driano J, Elger B, Lentino A, Driscoll M, Tidwell E, Sharma A, Walker SR, Jones G, Sharma P, Stessman H, Wu Y, Vadgama J, Chase D, Conrad L, Reddy ST, Farias-Eisner R. PMID: 33644256.
      View in: PubMed   Mentions:
    3. Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020 12 11; 11(12):1052. Hao Q, Wang P, Dutta P, Chung S, Li Q, Wang K, Li J, Cao W, Deng W, Geng Q, Schrode K, Shaheen M, Wu K, Zhu D, Chen QH, Chen G, Elshimali Y, Vadgama J, Wu Y. PMID: 33311440.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Nicotine Synergizes with High-Fat Diet to Induce an Anti-Inflammatory Microenvironment to Promote Breast Tumor Growth. Mediators Inflamm. 2020; 2020:5239419. Jimenez T, Friedman T, Vadgama J, Singh V, Tucker A, Collazo J, Sinha S, Hikim AS, Singh R, Pervin S. PMID: 33414685.
      View in: PubMed   Mentions:    Fields:    
    5. Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers. Cancers (Basel). 2020 Jul 16; 12(7). Wu Y, Sarkissyan M, Ogah O, Kim J, Vadgama JV. PMID: 32708561.
      View in: PubMed   Mentions:
    6. CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020 05 29; 18(1):82. Hao Q, Vadgama JV, Wang P. PMID: 32471499.
      View in: PubMed   Mentions: 11     Fields:    
    7. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells. Mol Cancer Ther. 2020 08; 19(8):1682-1695. Dillard C, Kiyohara M, Mah V, McDermott SP, Bazzoun D, Tsui J, Chan AM, Haddad G, Pellegrini M, Chang YL, Elshimali Y, Wu Y, Vadgama JV, Kim SR, Goodglick L, Law SM, Patel DD, Dhawan P, O'Brien NA, Gordon LK, Braun J, Lazar G, Wicha MS, Wadehra M. PMID: 32451329.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    8. Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer. Cancers (Basel). 2020 May 21; 12(5). Dutta P, Paico K, Gomez G, Wu Y, Vadgama JV. PMID: 32455851.
      View in: PubMed   Mentions:
    9. Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. J Clin Med. 2020 Mar 30; 9(4). Keung MY, Wu Y, Badar F, Vadgama JV. PMID: 32235451.
      View in: PubMed   Mentions:
    10. The role of PPM1D in cancer and advances in studies of its inhibitors. Biomed Pharmacother. 2020 May; 125:109956. Deng W, Li J, Dorrah K, Jimenez-Tapia D, Arriaga B, Hao Q, Cao W, Gao Z, Vadgama J, Wu Y. PMID: 32006900.
      View in: PubMed   Mentions: 1     Fields:    Translation:Cells
    11. Arctigenin inhibits prostate tumor growth in high-fat diet fed mice through dual actions on adipose tissue and tumor. Sci Rep. 2020 Jan 29; 10(1):1403. Hao Q, Diaz T, Verduzco ADR, Magyar CE, Zhong J, Elshimali Y, Rettig MB, Henning SM, Vadgama JV, Wang P. PMID: 31996731.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    12. Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice. J Cancer Res Ther Oncol. 2020; 8(1). Su F, Gm A, Palgunachari MN, White CR, Stessman H, Wu Y, Vadgama J, Pietras R, Nguyen D, Reddy ST, Farias-Eisner R. PMID: 32462055.
      View in: PubMed   Mentions:
    13. PP2Cd inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer. Sci Adv. 2019 10; 5(10):eaaw8417. Li Q, Hao Q, Cao W, Li J, Wu K, Elshimali Y, Zhu D, Chen QH, Chen G, Pollack JR, Vadgama J, Wu Y. PMID: 31663018.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    14. A novel curcumin analog inhibits canonical and non-canonical functions of telomerase through STAT3 and NF-?B inactivation in colorectal cancer cells. Oncotarget. 2019 Jul 16; 10(44):4516-4531. Chung SS, Dutta P, Chard N, Wu Y, Chen QH, Chen G, Vadgama J. PMID: 31360301.
      View in: PubMed   Mentions: 6     Fields:    
    15. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med. 2019 Mar 30; 8(4). Keung MYT, Wu Y, Vadgama JV. PMID: 30934991.
      View in: PubMed   Mentions:
    16. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance. Sci Rep. 2019 03 26; 9(1):5141. Nava M, Dutta P, Farias-Eisner R, Vadgama JV, Wu Y. PMID: 30914750.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    17. A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of different racial and ethnic backgrounds. J Cancer Metastasis Treat. 2019; 5. Kaufman M, Cruz A, Thompson J, Reddy S, Bansal N, Cohen JG, Wu Y, Vadgama J, Farias-Eisner R. PMID: 31236478.
      View in: PubMed   Mentions:
    18. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019 02 21; 21(1):29. Cao W, Li J, Hao Q, Vadgama JV, Wu Y. PMID: 30791936.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    19. The Research Centers in Minority Institutions (RCMI) Translational Research Network: Building and Sustaining Capacity for Multi-Site Basic Biomedical, Clinical and Behavioral Research. Ethn Dis. 2019; 29(Suppl 1):135-144. Ofili EO, Tchounwou PB, Fernandez-Repollet E, Yanagihara R, Akintobi TH, Lee JE, Malouhi M, Garner ST, Hayes TT, Baker AR, Dent AL, Abdelrahim M, Rollins L, Chang SP, Sy A, Hernandez BY, Bullard PL, Noel RJ, Shiramizu B, Hedges JR, Berry MJ, Bond VC, Lima MF, Mokuau N, Kirken RA, Cruz-Correa M, Sarpong DF, Vadgama J, Yates C, Kahn SA, Soliman KF, Perry G, Pezzano M, Luciano CA, Barnett ME, Oyekan A, Kumar D, Norris KC, RCMI Investigators and RTRN Team Members . PMID: 30906162.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets. BMC Med Genomics. 2019 02 08; 12(1):32. Nava M, Dutta P, Zemke NR, Farias-Eisner R, Vadgama JV, Wu Y. PMID: 30736768.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    21. Celecoxib in breast cancer prevention and therapy. Cancer Manag Res. 2018; 10:4653-4667. Li J, Hao Q, Cao W, Vadgama JV, Wu Y. PMID: 30464589.
      View in: PubMed   Mentions:
    22. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 2018 Sep 21; 9(74):33912-33930. Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. PMID: 30338035.
      View in: PubMed   Mentions: 10     Fields:    
    23. Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget. 2018 Aug 31; 9(68):32943-32957. Chung SS, Dutta P, Austin D, Wang P, Awad A, Vadgama JV. PMID: 30250641.
      View in: PubMed   Mentions: 7     Fields:    
    24. Targeting of PP2Cd By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo. Antioxid Redox Signal. 2019 06 10; 30(17):1983-1998. Wu K, Yu X, Huang Z, Zhu D, Yi X, Wu YL, Hao Q, Kemp KT, Elshimali Y, Iyer R, Nguyen KT, Zheng S, Chen G, Chen QH, Wang G, Vadgama JV, Wu Y. PMID: 29808718.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    25. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat. 2018 Aug; 170(3):477-486. Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama JV. PMID: 29594759.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    26. Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol. 2018; 1(2). Elshimali YI, Wu Y, Khaddour H, Wu Y, Gradinaru D, Sukhija H, Chung SS, Vadgama JV. PMID: 29932172.
      View in: PubMed   Mentions:
    27. Time to Clinical Follow-up after Abnormal Mammogram among African American and Hispanic Women. J Health Care Poor Underserved. 2018; 29(1):448-462. Petersen SS, Sarkissyan M, Wu Y, Clayton S, Vadgama JV. PMID: 29503311.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11). Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. PMID: 29099049.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    29. Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. Cancers (Basel). 2017 Oct 24; 9(10). Wu Y, Sarkissyan M, Clayton S, Chlebowski R, Vadgama JV. PMID: 29064397.
      View in: PubMed   Mentions:
    30. Proinflammatory Cytokines IL-6 and TNF-a Increased Telomerase Activity through NF-?B/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells. Mediators Inflamm. 2017; 2017:5958429. Chung SS, Wu Y, Okobi Q, Adekoya D, Atefi M, Clarke O, Dutta P, Vadgama JV. PMID: 28676732.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    31. GROa overexpression drives cell migration and invasion in triple negative breast cancer cells. Oncol Rep. 2017 Jul; 38(1):21-30. Bhat K, Sarkissyan M, Wu Y, Vadgama JV. PMID: 28560447.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    32. Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp. 2017 Jun; 13:1-11. Wang P, Solorzano W, Diaz T, Magyar CE, Henning SM, Vadgama JV. PMID: 29062885.
      View in: PubMed   Mentions:
    33. A83-01 inhibits TGF-ß-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3):449-460. Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV. PMID: 28337662.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    34. Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells. Anticancer Res. 2017 02; 37(2):445-453. Chung SS, Adekoya D, Enenmoh I, Clarke O, Wang P, Sarkyssian M, Wu Y, Vadgama JV. PMID: 28179289.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    35. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res. 2017 03 15; 77(6):1383-1394. Wu Y, Yu X, Yi X, Wu K, Dwabe S, Atefi M, Elshimali Y, Kemp KT, Bhat K, Haro J, Sarkissyan M, Vadgama JV. PMID: 28115363.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    36. Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators Inflamm. 2016; 2016:6456018. Wu Y, Dong Y, Atefi M, Liu Y, Elshimali Y, Vadgama JV. PMID: 28077918.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    37. Long-term exposure of MCF-7 breast cancer cells to ethanol stimulates oncogenic features. Int J Oncol. 2017 Jan; 50(1):49-65. Gelfand R, Vernet D, Bruhn KW, Sarkissyan S, Heber D, Vadgama JV, Gonzalez-Cadavid NF. PMID: 27959387.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    38. Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech. 2017 Apr; 3(1). Wu Y, Vadgama JV. PMID: 28474005.
      View in: PubMed   Mentions:
    39. Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol. 2016 Aug; 49(2):487-98. Chung SS, Oliva B, Dwabe S, Vadgama JV. PMID: 27279256.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    40. Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin Cancer Res. 2016 May 06; 35:73. Wang P, Henning SM, Magyar CE, Elshimali Y, Heber D, Vadgama JV. PMID: 27151407.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    41. Long-term exposure of MCF-12A normal human breast epithelial cells to ethanol induces epithelial mesenchymal transition and oncogenic features. Int J Oncol. 2016 Jun; 48(6):2399-414. Gelfand R, Vernet D, Bruhn K, Vadgama J, Gonzalez-Cadavid NF. PMID: 27035792.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    42. Diabetes-associated dysregulated cytokines and cancer. Integr Cancer Sci Ther. 2016 Feb; 3(1):370-378. Wu Y, Liu Y, Dong Y, Vadgama J. PMID: 29930868.
      View in: PubMed   Mentions:
    43. Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med. 2016 Jan 26; 5(2). Wu Y, Sarkissyan M, Vadgama JV. PMID: 26821054.
      View in: PubMed   Mentions:
    44. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PLoS One. 2015; 10(8):e0134948. Chung S, Dwabe S, Elshimali Y, Sukhija H, Aroh C, Vadgama JV. PMID: 26258407.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    45. Understanding Perceived Benefit of Early Cancer Detection: Community-Partnered Research with African American Women in South Los Angeles. J Womens Health (Larchmt). 2015 Sep; 24(9):755-61. Bazargan M, Lucas-Wright A, Jones L, Vargas R, Vadgama JV, Evers-Manly S, Maxwell AE. PMID: 26131760.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    46. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Breast Cancer Res Treat. 2015 Jun; 151(3):529-39. Wu Y, Sarkissyan M, Mcghee E, Lee S, Vadgama JV. PMID: 25975952.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    47. Biologic roles of estrogen receptor-ß and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int. 2015; 2015:925703. Hamilton N, Márquez-Garbán D, Mah V, Fernando G, Elshimali Y, Garbán H, Elashoff D, Vadgama J, Goodglick L, Pietras R. PMID: 25874233.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    48. Slug contributes to cancer progression by direct regulation of ERa signaling pathway. Int J Oncol. 2015 Apr; 46(4):1461-72. Li Y, Wu Y, Abbatiello TC, Wu WL, Kim JR, Sarkissyan M, Sarkissyan S, Chung SS, Elshimali Y, Vadgama JV. PMID: 25652255.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    49. Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015 Apr; 26(4):408-15. Wang P, Henning SM, Heber D, Vadgama JV. PMID: 25655047.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    50. Estrogen Receptor-ß and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90. Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. PMID: 27279236.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    51. Epigenetics in breast and prostate cancer. Methods Mol Biol. 2015; 1238:425-66. Wu Y, Sarkissyan M, Vadgama JV. PMID: 25421674.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    52. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NF?B signaling. Anticancer Res. 2015 Jan; 35(1):39-46. Chung SS, Vadgama JV. PMID: 25550533.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    53. Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells. Mol Nutr Food Res. 2015 Feb; 59(2):250-61. Wang P, Phan T, Gordon D, Chung S, Henning SM, Vadgama JV. PMID: 25380086.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    54. Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Adv. 2014 Aug 05; 4(66):35242-35250. Wang P, Wang B, Chung S, Wu Y, Henning SM, Vadgama JV. PMID: 25243063.
      View in: PubMed   Mentions:
    55. IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PLoS One. 2014; 9(7):e103534. Sarkissyan S, Sarkissyan M, Wu Y, Cardenas J, Koeffler HP, Vadgama JV. PMID: 25062088.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    56. Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice. BMC Cancer. 2014 Apr 17; 14:266. Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV. PMID: 24742286.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    57. Vitamin D receptor FokI gene polymorphisms may be associated with colorectal cancer among African American and Hispanic participants. Cancer. 2014 May 01; 120(9):1387-93. Sarkissyan M, Wu Y, Chen Z, Mishra DK, Sarkissyan S, Giannikopoulos I, Vadgama JV. PMID: 24510435.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    58. Correlates of perceived risk of developing cancer among African-Americans in South Los Angeles. J Community Health. 2014 Feb; 39(1):173-80. Lucas-Wright A, Bazargan M, Jones L, Vadgama JV, Vargas R, Sarkissyan M, Smith J, Yazdanshenas H, Maxwell AE. PMID: 24026303.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    59. A community partnered-participatory research approach to reduce cancer disparities in South Los Angeles. Prog Community Health Partnersh. 2014; 8(4):471-6. Vargas R, Maxwell AE, Lucas-Wright A, Bazargan M, Barlett C, Jones F, Brown A, Forge N, Smith J, Vadgamma J, Jones L. PMID: 25727979.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    60. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS One. 2013; 8(12):e83971. Chung SS, Aroh C, Vadgama JV. PMID: 24386318.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    61. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014 Feb; 44(2):403-11. Chung SS, Giehl N, Wu Y, Vadgama JV. PMID: 24297508.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    62. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. PLoS One. 2013; 8(10):e78259. Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV. PMID: 24167614.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    63. Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem. 2014 Jan; 25(1):73-80. Wang P, Vadgama JV, Said JW, Magyar CE, Doan N, Heber D, Henning SM. PMID: 24314868.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    64. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013 Sep 13; 14(9):18925-58. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. PMID: 24065096.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCells
    65. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6109-14. Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP. PMID: 23536305.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    66. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One. 2013; 8(3):e57967. Mishra DK, Wu Y, Sarkissyan M, Sarkissyan S, Chen Z, Shang X, Ong M, Heber D, Koeffler HP, Vadgama JV. PMID: 23554871.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    67. Comparing perceived and test-based knowledge of cancer risk and prevention among Hispanic and African Americans: an example of community participatory research. Ethn Dis. 2013; 23(2):210-6. Jones L, Bazargan M, Lucas-Wright A, Vadgama JV, Vargas R, Smith J, Otoukesh S, Maxwell AE. PMID: 23530303.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    68. Expression of Wnt3 activates Wnt/ß-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012 Dec; 10(12):1597-606. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. PMID: 23071104.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCells
    69. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2012; 2(1):104-15. Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV. PMID: 22206049.
      View in: PubMed   Mentions:
    70. IGF gene polymorphisms and breast cancer in African-American and Hispanic women. Int J Oncol. 2011 Jun; 38(6):1663-73. Sarkissyan M, Mishra DK, Wu Y, Shang X, Sarkissyan S, Vadgama JV. PMID: 21455574.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol. 2011 Jun; 38(6):1741-7. Chien W, O'Kelly J, Lu D, Leiter A, Sohn J, Yin D, Karlan B, Vadgama J, Lyons KM, Koeffler HP. PMID: 21455569.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    72. Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer. 2011 Aug 15; 117(16):3814-23. Sarkissyan M, Wu Y, Vadgama JV. PMID: 21305540.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    73. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer. 2010 Nov 15; 127(10):2257-67. Yin D, Chen W, O'Kelly J, Lu D, Ham M, Doan NB, Xie D, Wang C, Vadgama J, Said JW, Black KL, Koeffler HP. PMID: 20162579.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    74. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010 Jul 01; 70(13):5475-85. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. PMID: 20551062.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    75. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 2010 Feb 04; 10:32. Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV. PMID: 20132554.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    76. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. . 2010 Jan; 9(1):33-45. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. PMID: 20053773.
      View in: PubMed   Mentions:
    77. Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res. 2008 Nov-Dec; 28(6A):3579-92. Thant AA, Wu Y, Lee J, Mishra DK, Garcia H, Koeffler HP, Vadgama JV. PMID: 19189638.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    78. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res. 2008; 10(1):R3. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. PMID: 18184439.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    79. Clinical significance of incidental colorectal wall thickening on computed tomography scan in African-American and Hispanic patients. Dig Dis Sci. 2007 Nov; 52(11):3159-64. Padda M, Vadgama J, Sandhu P, Dev A, Giannikopoulos I. PMID: 17404851.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    80. Taxol induced apoptosis regulates amino acid transport in breast cancer cells. Apoptosis. 2007 Mar; 12(3):593-612. Wu Y, Shen D, Chen Z, Clayton S, Vadgama JV. PMID: 17195090.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    81. Insulin-like growth factor I differentially regulates the expression of HIRF1/hCAF1 and BTG1 genes in human MCF-7 breast cancer cells. Int J Mol Med. 2006 Jul; 18(1):129-39. Vadgama JV, Scuric Z, Chakrabarti R, Marzo E, Shen D, Wu Y. PMID: 16786164.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    82. Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. J Steroid Biochem Mol Biol. 2006 Aug; 100(4-5):107-16. O'Kelly J, Uskokovic M, Lemp N, Vadgama J, Koeffler HP. PMID: 16777406.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    83. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res. 2005 May 01; 11(9):3184-90. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP. PMID: 15867211.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    84. Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci U S A. 2003 Apr 01; 100(7):3913-8. Bhat HK, Calaf G, Hei TK, Loya T, Vadgama JV. PMID: 12655060.
      View in: PubMed   Mentions: 45     Fields:    Translation:Animals
    85. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol. 2002 Mar; 20(3):509-16. Wu Y, Saldana L, Chillar R, Vadgama JV. PMID: 11836562.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    86. Role of estrogen receptor in the regulation of estrogen induced amino acid transport of System A in breast cancer and other receptor positive tumor cells. Int J Mol Med. 2002 Mar; 9(3):271-9. Bhat HK, Vadgama JV. PMID: 11836633.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    87. TNF-alpha in trauma patients: a touch is just enough. Curr Surg. 2000 Nov; 57(6):638. Pellegrin K, Peterson VM, Vadgama J, Wu Y, Fleming AW. PMID: 11120320.
      View in: PubMed   Mentions:    Fields:    
    88. Identification and characterization of amino acid starvation-induced CD24 gene in MCF-7 human breast cancer cells. Int J Oncol. 2000 May; 16(5):1049-54. Liu W, Vadgama JV. PMID: 10762644.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    89. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res. 2000 May-Jun; 20(3A):1391-414. Vadgama JV, Wu Y, Shen D, Hsia S, Block J. PMID: 10928049.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    90. Missense alterations of BRCA1 gene detected in diverse cancer patients. Anticancer Res. 2000 Mar-Apr; 20(2B):1129-32. Shen D, Wu Y, Chillar R, Vadgama JV. PMID: 10810408.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    91. Mutation analysis of BRCA1 gene in African-American patients with breast cancer. J Natl Med Assoc. 2000 Jan; 92(1):29-35. Shen D, Wu Y, Subbarao M, Bhat H, Chillar R, Vadgama JV. PMID: 10800284.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    92. Hamster estrogen receptor cDNA: cloning and mRNA expression. J Steroid Biochem Mol Biol. 2000 Jan-Feb; 72(1-2):47-53. Bhat HK, Vadgama JV. PMID: 10731637.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    93. A truncated BRCA1 gene mutation identified in a Hispanic American breast cancer patient with family history. Medicine of the Americas (formerly Southwest Journal of Medicine). 2000; (1):15-19. Shen D, Wu Y, Chillar R, Vadgama JV. .
    94. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology. 1999 Nov; 57(4):330-40. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. PMID: 10575321.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    95. Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer. Int J Oncol. 1999 Jun; 14(6):1021-37. Wu Y, Khan H, Chillar R, Vadgama JV. PMID: 10339653.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    96. BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC). Oncol Res. 1999; 11(2):63-9. Shen D, Vadgama JV. PMID: 10489161.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    97. Elevated basal cytosolic calcium attenuates IGF-I stimulation of protein synthesis in cardiomyocytes of rats with chronic renal failure. Journal of the American Society of Nephrology. 1999; (10):84-92. Qing DP, Ding H, Vadgama JV, Wu Y, Kopple JD.
    98. Accumulation of albumin in renal cytosol of hamsters treated with estradiol and in estrogen-induced hamster kidney tumors. Int J Oncol. 1998 Nov; 13(5):1087-91. Bhat HK, Vadgama JV, Liehr JG. PMID: 9772304.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    99. Amino Acid Transport in Keloid Fibroblast. Investigative Dermatology. 1995. Vadgama JV, Chang KC, Franklin KM, Kelly AP.
    100. Role of Glutamine in Regulating Glutamine Transport & Globin Gene Expression in Human Erythroleukemia Cells K562. 3rd International Congress on Amino Acids, Peptides, & Analogues. Amino Acids. 1993; 203(5). Vadgama JV, Chang K, Chang B, Lin HJ.
    101. Lysosomal transport of small molecules. Biochem Med Metab Biol. 1992 Dec; 48(3):179-93. Chou HF, Vadgama J, Jonas AJ. PMID: 1476786.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    102. Absorption of amino acids from the human mouth. Amino Acids. 1992 Oct; 3(3):271-86. Vadgama JV, Evered DF. PMID: 24193127.
      View in: PubMed   Mentions:    Fields:    
    103. Lysosomal sulfate transport. Pathophysiology of Lysosomal Transport. 1992; 133-154. Vadgama JV, Jonas AJ.
    104. Characterization of threonine transport into a kidney epithelial cell line (BSC-1). Evidence for the presence of Na(+)-independent system asc [corrected]. J Biol Chem. 1991 Aug 15; 266(23):15042-7. Kuhlmann MK, Vadgama JV. PMID: 1907970.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    105. Characteristics of taurine transport in rat liver lysosomes. J Cell Physiol. 1991 Jun; 147(3):447-54. Vadgama JV, Chang K, Kopple JD, Idriss JM, Jonas AJ. PMID: 2066365.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    106. Differential expression of amino acid transport systems A and ASC during erythroleukemia cell differentiation. Am J Physiol. 1991 Mar; 260(3 Pt 1):C392-9. Vadgama JV, Chan MN, Wu JM. PMID: 1900666.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    107. Nutritional and Metabolic Implications of Acute Renal Failure. Renal Nutrition. 1991; 58-64. Brunori G, Leiserowitz M, Shamir E, Kuhlmann M, Vadgama JV, Kopple JD.
    108. Design of simple devices to measure solute fluxes and binding in monolayer cell cultures. Methods Enzymol. 1989; 171:133-44. Vadgama JV. PMID: 2593839.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    109. Characterization of amino acid transport during erythroid cell differentiation. J Biol Chem. 1987 Sep 25; 262(27):13273-84. Vadgama JV, Castro M, Christensen HN. PMID: 3654612.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    110. A new Na+-independent transport system for dipolar amino acids apparently corresponding to systems persisting after erythrocyte maturation in some mammalian genotypes. Ann N Y Acad Sci. 1985; 456:454-6. Vadgama JV, Christensen HN. PMID: 3937471.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    111. Naming plan for membrane transport systems for amino acids. Neurochem Res. 1984 Dec; 9(12):1757-8. Christensen HN. PMID: 6531071.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    112. Amino acid transport systems. Nature. 1984 Sep 27-Oct 3; 311(5984):308. Bannai S, Christensen HN, Vadgama JV, Ellory JC, Englesberg E, Guidotti GG, Gazzola GC, Kilberg MS, Lajtha A, Sacktor B. PMID: 6482960.
      View in: PubMed   Mentions: 22     Fields:    Translation:Animals
    113. Wide distribution of pH-dependent service of transport system ASC for both anionic and zwitterionic amino acids. J Biol Chem. 1984 Mar 25; 259(6):3648-52. Vadgama JV, Christensen HN. PMID: 6423635.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    114. Synthesis and transport applications of 3-aminobicyclo[3.2.1] octane-3-carboxylic acids. J Med Chem. 1983 Oct; 26(10):1374-8. Christensen HN, Handlogten ME, Vadgama JV, de la Cuesta E, Ballesteros P, Trigo GG, Avendaño C. PMID: 6413692.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    115. Comparison of system N in fetal hepatocytes and in related cell lines. J Biol Chem. 1983 May 25; 258(10):6422-9. Vadgama JV, Christensen HN. PMID: 6304040.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    116. Absorption of homocitrulline from the gastrointestinal tract. Br J Nutr. 1983 Jan; 49(1):35-42. Evered DF, Vadgama JV. PMID: 6821687.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    117. Changes in Amino Acid Transport Systems on Maturation and Transformation of Rat Hepatocytes. Isolation, Characterization, and Use of Hepatocytes. 1983; 217-226. Christensen HN, Makowske M, Vadgama JV. .
    118. Absorption of amino acids from the human buccal cavity. Biochem Soc Trans. 1981 Feb; 9(1):132-3. Evered DF, Vadgama JV. PMID: 7215641.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Jaydutt's Networks
    Concepts (492)
    Derived automatically from this person's publications.
    Co-Authors (21)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department